Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine
Status:
Completed
Trial end date:
2005-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to perform Phase 1 (safety/toxicity and pharmacokinetic)
Studies of an investigational aminoquinoline antimalarial (AQ-13) in human subjects. The
compound to be studied (AQ-13) is being examined because it is active in vitro against
Plasmodium falciparum malaria parasites resistant to chloroquine (CQ) and other antimalarials
(multi-resistant P. falciparum), and because its safety was similar to that of CQ in
preclinical studies performed by SRI International (IND 55,670). AQ-13 was also selected for
study because it is active in vivo in two monkey models of human malaria: 1] P. cynomolgi in
the rhesus monkey (Macaca mulatta), a model of human infection with P. vivax, and 2]
CQ-resistant P. falciparum in the squirrel monkey, a model of human infection with
CQ-resistant P. falciparum.
Phase:
Phase 1
Details
Lead Sponsor:
Tulane University Health Sciences Center
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH)